Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.
J Infect Dis
; 204 Suppl 3: S785-90, 2011 Nov.
Article
em En
| MEDLINE
| ID: mdl-21987751
ABSTRACT
A needlestick injury occurred during an animal experiment in the biosafety level 4 laboratory in Hamburg, Germany, in March 2009. The syringe contained Zaire ebolavirus (ZEBOV) mixed with Freund's adjuvant. Neither an approved treatment nor a postexposure prophylaxis (PEP) exists for Ebola hemorrhagic fever. Following a risk-benefit assessment, it was recommended the exposed person take an experimental vaccine that had shown PEP efficacy in ZEBOV-infected nonhuman primates (NHPs) [12]. The vaccine, which had not been used previously in humans, was a live-attenuated recombinant vesicular stomatitis virus (recVSV) expressing the glycoprotein of ZEBOV. A single dose of 5 × 10(7) plaque-forming units was injected 48 hours after the accident. The vaccinee developed fever 12 hours later and recVSV viremia was detectable by polymerase chain reaction (PCR) for 2 days. Otherwise, the person remained healthy, and ZEBOV RNA, except for the glycoprotein gene expressed in the vaccine, was never detected in serum and peripheral blood mononuclear cells during the 3-week observation period.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ferimentos Penetrantes Produzidos por Agulha
/
Doença pelo Vírus Ebola
/
Vacinas contra Ebola
/
Ebolavirus
/
Profilaxia Pós-Exposição
/
Infecção Laboratorial
Limite:
Animals
/
Humans
País/Região como assunto:
Europa
Idioma:
En
Revista:
J Infect Dis
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
Alemanha